Kjell G. Stenberg, CEO of Cyxone, commented: "I recently returned from a successful partnering conference, Nordic Life Science Days, held this week in Malmö. It was great fun to meet several new contacts and update existing contacts with the latest progress we have made with the portfolio. Our candidates have great potential, which is why I choose to expand my private holdings further."

CEO Kjell G. Stenberg har earlier this year expanded his private holding in Cyxone with a total of 17,888 shares to the total value of 114,000 SEK.

Contact
Cyxone AB (publ)
Kjell G. Stenberg, CEO
Phone: +46 (0) 723 816 168
Email: kjell.g.stenberg@cyxone.com
Adelgatan 21
211 22 Malmö, Sweden

About Cyxone
Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company's drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body's cells that are typically associated with various immune-related disorders. Cyxone's technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in clinical phase I program and Rabeximod for RA in clinical phase II program. Cyxone's Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, +46 (0)8-503 015 50, ca@mangold.se.www.cyxone.com